Drug-delivering particles aim to breach the blood–brain barrier

Nanoparticle- and exosome-based drug delivery platforms are advancing as strategies to overcome the blood–brain barrier, a decades-old obstacle to treating brain tumours and neurodegenerative diseases. Nature reviews competing approaches that aim to ferry therapeutics across the barrier selectively, potentially improving outcomes for gliomas and other CNS malignancies. No single technique has yet achieved broad clinical validation, but multiple platforms are in active preclinical and early clinical testing.